US WorldMeds Completes Acquisition of Adaptimmune's Cell-Therapy Portfolio, Ensures Continued Patient Access to TECELRA
Reuters
Aug 05
US WorldMeds Completes Acquisition of Adaptimmune's Cell-Therapy Portfolio, Ensures Continued <a href="https://laohu8.com/S/PASO">Patient Access</a> to TECELRA
US WorldMeds (USWM) has successfully completed the acquisition of Adaptimmune Therapeutics plc's cell-therapy assets. The acquisition, initially announced on July 28, 2025, includes TECELRA®, lete-cel, afami-cel, and uza-cel. USWM paid $55 million in cash at closing and may provide up to an additional $30 million in performance-based milestone payments. TECELRA, a genetically modified T cell immunotherapy for synovial sarcoma, will remain available to patients without interruption. USWM also plans to bring lete-cel to the U.S. market, with potential regulatory approval expected in 2026, and will continue developing uza-cel in collaboration with Galapagos. Approximately half of Adaptimmune's U.S.-based workforce will join USWM to support these efforts. Adaptimmune will offer transition services until June 2026 to ensure operational continuity.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adaptimmune Therapeutics plc published the original content used to generate this news brief via PR Newswire (Ref. ID: NY43551) on August 04, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.